...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of STD & AIDS >Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort
【24h】

Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort

机译：RATEGRAVIR的抗逆转录病毒治疗在艾滋病毒感染患者中的类似疗效和耐受性，无论年龄组，合并症的负担和伴随药物的负担：德国'WIP'队列的现实生活分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Only limited efficacy and tolerability data on raltegravir (RAL) use are currently available. Study objectives were to describe the efficacy and tolerability profile of RAL-based antiretroviral therapy (ART) in routine clinical practice in Germany. The WIP study (WIP = "Wirksamkeit von Isentress unter Praxisbedingungen'', Efficacy of Isentress under routine clinical conditions) was a prospective, multi-centre cohort study in Germany. Human immunodeficiency virus (HIV)-infected patients aged >= 18 years in whom combinational ART with RAL 400 mg BID was indicated were enrolled. The primary endpoint was virologic response (HIV-RNA <50 copies/mL; non-completion equals failure) after 48 weeks. Of 451 patients, 85.1% (n = 384) were still receiving RAL at week 48. At baseline (BL), the prevalence of concomitant diseases was higher in patients of the age group >= 50 years (94.2% vs. 75.7%) as well as concomitant medications (74.8 % vs. 55.4%). Virologic response at week 48 was 74.7% (overall), 75.0% (naive at BL), 81.5% (suppressed at BL), 47.1% (interrupted previous treatment at BL) and 64.9% (failing at BL), without significant differences by age group. A significant correlation of achievement of HIV-RNA < 50 copies/mL was seen with treatment status at BL (p = 0.004). In addition, 77.3 % of the patients with a CD4 cell count > 200 cells/mL at BL achieved HIV-RNA <50 copies/mL (p = 0.029). RAL was well tolerated with 80 adverse events (AEs) in 49 patients (10.9%) and 8 serious AEs (SAEs) in 6 patients (1.3%) reported to be drug related. A total of 22 patients (4.9%) discontinued treatment due to AEs. The WIP study shows that the previously reported efficacy and safety profile of RAL can be achieved in a population with multiple comorbidities and comedications, with no major difference observed in ageing patients (>= 50 years) vs. younger patients. RAL is therefore an attractive treatment option in routine medical care in Germany.
机译：目前只有有限的有限功效和耐受性数据使用RALTEGRAVIR（RAL）使用。研究目标是描述RAL型抗逆转录病毒治疗（ART）在德国常规临床实践中的疗效和耐受性谱。 WIP研究（WIP =“WIRKSAMKEIT VON ISENTRASS ONTER PRAXISBEDENGEN''，常规临床条件下的ISENTRASS的疗效）是德国的前瞻性多中心队列研究。人类免疫缺陷病毒（HIV） - 育龄患者= 18岁注册了400mg出价的组合艺术。初级终点是病毒学反应（HIV-RNA <50拷贝/ mL;未完成等于失败）。451名患者，85.1％（n = 384）在第48周仍然接受RAL。在基线（BL），年龄组患者的伴随疾病的患病率较高> = 50岁（94.2％与75.7％）以及伴随药物（74.8％与55.4 ％）。第48周的病毒学反应为74.7％（总体），75.0％（BL），81.5％（BL），47.1％（在BL）中断，64.9％（BL）（BL）未发生），没有年龄组的显着差异。用TR看到HIV-RNA的成就<50拷贝/ mL的显着相关性BL（p = 0.004）的酸味状态。此外，77.3％的患者CD4细胞计数> BL的CD4细胞计数/ mL达到HIV-RNA <50拷贝/ mL（P = 0.029）。在4例患者（10.9％）和8名患者中的8名患者（10.9％）和8名严重的AES（SAES）中，RAL耐受良好耐受，据报道有关的药物有关。由于AES，共有22名患者（4.9％）停止治疗。 WIP的研究表明，先前报道的RAL的疗效和安全性曲线可以在具有多种合并症和可展示的人群中实现，并且在老化患者（> = 50年）中没有观察到的主要差异与较年轻的患者。因此，RAL是德国常规医疗的有吸引力的治疗选择。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号